» Articles » PMID: 19860577

Revised American Thyroid Association Management Guidelines for Patients with Thyroid Nodules and Differentiated Thyroid Cancer

Overview
Journal Thyroid
Date 2009 Oct 29
PMID 19860577
Citations 2196
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Thyroid nodules are a common clinical problem, and differentiated thyroid cancer is becoming increasingly prevalent. Since the publication of the American Thyroid Association's guidelines for the management of these disorders was published in 2006, a large amount of new information has become available, prompting a revision of the guidelines.

Methods: Relevant articles through December 2008 were reviewed by the task force and categorized by topic and level of evidence according to a modified schema used by the United States Preventative Services Task Force.

Results: The revised guidelines for the management of thyroid nodules include recommendations regarding initial evaluation, clinical and ultrasound criteria for fine-needle aspiration biopsy, interpretation of fine-needle aspiration biopsy results, and management of benign thyroid nodules. Recommendations regarding the initial management of thyroid cancer include those relating to optimal surgical management, radioiodine remnant ablation, and suppression therapy using levothyroxine. Recommendations related to long-term management of differentiated thyroid cancer include those related to surveillance for recurrent disease using ultrasound and serum thyroglobulin as well as those related to management of recurrent and metastatic disease.

Conclusions: We created evidence-based recommendations in response to our appointment as an independent task force by the American Thyroid Association to assist in the clinical management of patients with thyroid nodules and differentiated thyroid cancer. They represent, in our opinion, contemporary optimal care for patients with these disorders.

Citing Articles

I SPECT/CT provides prognostic information in patients with differentiated thyroid cancer.

Heinrich M, Blickle E, Hartrampf P, Hasenauer N, Kosmala A, Kerscher A Eur J Nucl Med Mol Imaging. 2025; .

PMID: 40088267 DOI: 10.1007/s00259-025-07187-1.


hsa_circ_0004846 enhances the malignant phenotype of papillary thyroid carcinoma cells via the miR‑142‑3p/PELI1 axis.

Ding X, Li R, Xu J, Hu G, Wang W, Lv Q Oncol Lett. 2025; 29(4):203.

PMID: 40070794 PMC: 11894512. DOI: 10.3892/ol.2025.14949.


Predicting central lymph node metastasis in papillary thyroid carcinoma combined with Hashimoto's thyroiditis: a preoperative study.

Lou P, Huang Y, Li H, Zhao F, Xu J, Wang K BMC Cancer. 2025; 25(1):425.

PMID: 40065226 PMC: 11892260. DOI: 10.1186/s12885-025-13805-w.


The Landmark Series: Extent of Surgery for Low-Risk Differentiated Thyroid Cancer.

Ullmann T, Sosa J Ann Surg Oncol. 2025; .

PMID: 40009309 DOI: 10.1245/s10434-025-17063-9.


A Method for Calculating Small Sizes of Volumes in Postsurgical Thyroid SPECT/CT Imaging.

Ttofi E, Kyriacou C, Leontiou T, Parpottas Y Life (Basel). 2025; 15(2).

PMID: 40003609 PMC: 11856228. DOI: 10.3390/life15020200.